Template to improve glycemic control without reducing adiposity or dietary fat. - Wikidata - awgldk - TriplyDB

Template to improve glycemic control without reducing adiposity or dietary fat.

Template to improve glycemic control without reducing adiposity or dietary fat.

http://www.wikidata.org/entity/Q34979386

about

Adenovirus 36 and Obesity: An Overview E4orf1: a novel ligand that improves glucose disposal in cell culture Serological data analyses show that adenovirus 36 infection is associated with obesity: a meta-analysis involving 5739 subjects.Adenovirus-36 is associated with obesity in children and adults in Sweden as determined by rapid ELISA.Natural infection of human adenovirus 36 in rhesus monkeys is associated with a reduction in fasting glucose 36 ADV36 adipogenic adenovirus in human liver disease.E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia.Adenovirus 36 attenuates weight loss from exercise but improves glycemic control by increasing mitochondrial activity in the liver.Harnessing the beneficial properties of adipogenic microbes for improving human health.PPARgamma-independent increase in glucose uptake and adiponectin abundance in fat cells.E4orf1 induction in adipose tissue promotes insulin-independent signaling in the adipocyte.E4orf1 Enhances Glucose Uptake Independent of Proximal Insulin Signaling.Long-term changes in adiposity and glycemic control are associated with past adenovirus infection.Insulin receptor-independent upregulation of cellular glucose uptake An adenovirus-derived protein: A novel candidate for anti-diabetic drug development.Hepatic Expression of Adenovirus 36 E4ORF1 Improves Glycemic Control and Promotes Glucose Metabolism Through AKT Activation.Doxycycline-regulated 3T3-L1 preadipocyte cell line with inducible, stable expression of adenoviral E4orf1 gene: a cell model to study insulin-independent glucose disposal.Adenovirus Protein E4-ORF1 Activation of PI3 Kinase Reveals Differential Regulation of Downstream Effector Pathways in Adipocytes.Insulin-sparing and fungible effects of E4orf1 combined with an adipocyte-targeting sequence in mouse models of type 1 and type 2 diabetes.Characteristics of adipose tissue macrophages and macrophage-derived insulin-like growth factor-1 in virus-induced obesity.Adenovirus 36 infection: a role in dietary intake and response to inpatient weight management in obese girls.Human adenovirus-36 is uncommon in type 2 diabetes and is associated with increased insulin sensitivity in adults in Sweden.Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36.High prevalence of HHV8 infection and specific killer cell immunoglobulin-like receptors allotypes in Sardinian patients with type 2 diabetes mellitus.Genomic stability of adipogenic human adenovirus 36.

P2860

Q26799943-409827F8-130E-4AD6-BBAB-A102890F8B61 Q28741118-B7825488-B070-48CA-B00D-19A15DC7B87B Q30651817-2CC923EA-B302-49C8-9744-598F7CD4CD79 Q34358763-56D3986A-459E-49D0-B86C-64DF47BB1EB7 Q34401501-F32B5F9F-49B5-46F7-B9FC-E48E3925AAD8 Q34405050-47999511-F48A-4595-9970-BD2C76E85F06 Q34460590-D69B8F02-272F-4C09-915F-76EEC8F9FA01 Q34640452-9A1F56ED-4B99-40D4-9268-E52746B5FFC9 Q34714843-264E9224-F390-4752-8100-B3DEBB2E922B Q35223008-52088B69-D807-451F-991F-6F5B7BE6067C Q36106341-F1201235-2172-4EF7-98DD-A5F5B59EEC17 Q36107128-CF33D38E-7DC1-4BA1-B0EA-3A56F4547785 Q36629576-C86E5D4C-20C1-4018-BBB5-156E8FA6606F Q36826889-D9C33C6E-2385-4E68-A6D9-9401D334284F Q37446084-1EFFA216-29F8-40F6-801E-E398E8AB1551 Q39141580-37944783-D004-436A-8168-34A5BD231658 Q39173157-07601A82-556B-41FE-A748-9D28F1ACC585 Q40076038-6A856798-DFAA-497E-8D83-C71A4ED86767 Q40162489-A9700057-0DF3-40F9-AD9B-EC188CF8EE04 Q40512953-E80A305A-16FE-43C9-A41A-05E27A57C9D0 Q41035719-F7B37B24-C6DF-48A3-8C5D-23CACD0133B4 Q42204806-4CD3E186-530B-44E2-A532-7DDB6D422469 Q42232577-6CD5EB0F-47B3-4D9A-A2A2-BF1EADA6B018 Q42244344-9623E436-A77C-42EC-B6F8-04CCA1962091 Q50940752-D0E13BF4-C7A2-44FF-8D96-89956A89E15F

P2860

Template to improve glycemic control without reducing adiposity or dietary fat.

http://www.wikidata.org/entity/Q34979386

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Template to improve glycemic control without reducing adiposity or dietary fat.

@ast

Template to improve glycemic control without reducing adiposity or dietary fat.

@en

Template to improve glycemic control without reducing adiposity or dietary fat.

@nl

type

label

Template to improve glycemic control without reducing adiposity or dietary fat.

@ast

Template to improve glycemic control without reducing adiposity or dietary fat.

@en

Template to improve glycemic control without reducing adiposity or dietary fat.

@nl

prefLabel

Template to improve glycemic control without reducing adiposity or dietary fat.

@ast

Template to improve glycemic control without reducing adiposity or dietary fat.

@en

Template to improve glycemic control without reducing adiposity or dietary fat.

@nl

P1433

Q34979386-FDD23529-EEB8-4F82-9BDE-AB1E99978A0E

P1476

Q34979386-81A5B171-4EE2-4EF4-A8DE-BB38D1435314

P2093

Q34979386-12ED4188-1ADB-4D0E-BFF3-F1A68064CB53

Q34979386-2687438F-FEC0-4A3A-A4B5-1925A899B334

Q34979386-279C3304-C1DB-4C4C-A5CB-72B65A6C9D2F

Q34979386-2AB29411-A773-4559-BF44-DBCEF6ABECC6

Q34979386-303BE7C3-CFF9-4382-9709-FFB03E057BEF

Q34979386-3B1BA087-19CB-4F1F-A5C8-4521CF6454B2

Q34979386-4DE9D2FC-C577-4F8C-8832-B715E035D02C

Q34979386-58F8035B-DE0B-4E7D-B592-1FFAFD49231A

Q34979386-8B43FB0F-FF97-4153-934E-7CFC2C453B26

Q34979386-8C542279-5539-4928-8C32-14D90AF97C3E

P2860

Q34979386-01E7C8D8-36B4-499B-B7A5-CB3404A6BE8F

Q34979386-064834B4-A5F5-4ACA-9382-6E4B397EC7F8

Q34979386-06C92B60-DDD2-486D-866F-28FE2EFD0E94

Q34979386-0958B011-C614-4278-B4D9-F6E2CA323E59

Q34979386-09A9F82C-9559-411C-B71A-29636826C6C4

Q34979386-0AD08B69-3613-44FE-BA4D-EEE8BAE1DD5A

Q34979386-0C4D3D5D-9763-4B38-8FFA-286391853E40

Q34979386-0CFF8BD3-F94A-40F5-ACF1-93A76990056B

Q34979386-0E58422B-6279-4F98-8643-284AB8E00FC1

Q34979386-11C8BDDB-7C63-44CA-A694-2B56A566F953

P304

Q34979386-5B9AE250-B215-43B1-97CD-7855EAA37983

P31

Q34979386-16591802-5503-412A-A979-366896177A01

P356

Q34979386-BAC1EFBC-D92F-46B6-9B5B-67CA3C5CAEAD

P433

Q34979386-28815F2E-4A97-4712-8B42-C75067A918B2

P478

Q34979386-4DA23F16-F113-46EE-994E-46BE21BEA33B

P577

Q34979386-EDC8FCE0-9E95-4F4A-9BFD-C3924D90F81F

P5875

Q34979386-C778E690-B399-4CB2-9D83-8A9595D83F58

P698

Q34979386-1CB8AAC5-8B10-4F51-8514-B96342B8131B

P932

Q34979386-EA773E87-2223-4649-9866-CF63B220EAB9

P356

AJPENDO.00703.2010

P1433

American Journal of Physiology - Endocrinology and Metabolism

P1476

Template to improve glycemic control without reducing adiposity or dietary fat.

@en

P2093

A K Gupta

http://www.w3.org/2001/XMLSchema#string

A Zuberi

http://www.w3.org/2001/XMLSchema#string

B Bennett

http://www.w3.org/2001/XMLSchema#string

C Bouchard

http://www.w3.org/2001/XMLSchema#string

E J Dhurandhar

http://www.w3.org/2001/XMLSchema#string

E Larsen-Meyer

http://www.w3.org/2001/XMLSchema#string

F L Greenway

http://www.w3.org/2001/XMLSchema#string

G Reinhart

http://www.w3.org/2001/XMLSchema#string

H Kirk-Ballard

http://www.w3.org/2001/XMLSchema#string

J Ye

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

Defects of the insulin receptor substrate (IRS) system in human metabolic disorders

Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

Long-term follow-up of patients with NAFLD and elevated liver enzymes

Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.

P304

E779-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPENDO.00703.2010

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

300

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49785131

http://www.w3.org/2001/XMLSchema#string

P698

21266671

http://www.w3.org/2001/XMLSchema#string

P932

3093976

http://www.w3.org/2001/XMLSchema#string